Fusion protein · Immune activation, directed at MHC class II molecules · developed by Immutep S.A.S.
Eftilagimod alpha is a soluble recombinant fusion protein derived from the extracellular Ig-like domains of the LAG-3 (CD223) protein. It binds with high affinity to MHC class II molecules on dendritic cells, promoting their maturation, migration to lymph nodes and cross-presentation of antigens to T cells. It is studied in combination with tumor antigens or paclitaxel in breast cancer, non-small cell lung cancer, soft tissue sarcoma and melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06726265 | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active not recruiting | IMMP |
| NCT05747794 | Phase 2/3 | Breast Carcinoma | Terminated | IMMP |
| NCT07102940 | Phase 2 | Breast Cancer | Not yet recruiting | IMMP |
| NCT06128863 | Phase 2 | Neoadjuvant | Active not recruiting | IMMP |
| NCT02614833 | Phase 2 | Adenocarcinoma Breast Stage IV | Completed | IMMP |
| NCT01308294 | Phase 1/2 | Melanoma | Terminated | IMMP |
| NCT00365937 | Phase 1/2 | Melanoma | Terminated | IMMP |
| NCT00354861 | Phase 1 | Healthy | Completed | IMMP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Breast CancerHER 2 Negative Breast CancerHR Positive/HER-2 Negative Breast CancerImmunotherapyNeoadjuvantRadiation TherapySarcoma,Soft TissueStage 1-3Adenocarcinoma Breast Stage IVBreast CarcinomaHealthyMelanoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMMP page.
See IMMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMMP catalysts and pipeline →